H.C. Wainwright raised its price target for PDS Biotechnology (NASDAQ:PDSB) to $20 from $8 ahead of additional data being released at the ASCO meeting this weekend. The stock closed at $10.86 on June 1. “We believe that...
PDS Biotechnology (NASDAQ: PDSB) expects to report preliminary data in the first or second quarter of 2021 from a collaboration with the NCI, evaluating its lead oncology product, PDS0101, for the treatment of advanced...
H.C. Wainwright upgraded PDS Biotechnology (NASDAQ:PDSB) to “buy” from “neutral” with a price target of $6. The stock closed at $2.04 on Nov. 9. In March 2020, HCW downgraded PDS based on dilution, significantly reduced...
H.C. Wainwright downgraded PDS Biotechnology (NASDAQ:PDSB) to “neutral” from “buy” and removed its price target, citing recent significant dilution and lack of meaningful catalysts over the remainder of the year “prompt...
H.C. Wainwright initiated coverage of PDS Biotechnology (NASDAQ:PDSB) with a “buy” rating and $7 price target. The stock closed at $3.05 on Nov. 4. PDS is developing anti-cancer therapeutics leveraging its proprietary...